{
  "abstract": "The 2025 to 2026 measles outbreak marked a significant resurgence of a vaccine-preventable disease, raising urgent public health concerns. The clinical implications of this outbreak for patients on immunosuppressive therapy, specifically in dermatology, remain poorly defined. This review addresses this gap, examining measles presentations and complications in immunosuppressed dermatology patients. We discuss diagnostic considerations specific to this population, in whom impaired humoral immunity can limit the reliability of standard testing. Finally, we propose a practical, dosing, and pharmokinetic-based framework for measles-mumps-rubella vaccination and postexposure prophylaxis decisions across commonly used dermatologic therapies. This includes specifically biologics, targeted small molecules, and conventional immunosuppressants. Current public health guidance was largely developed from oncology, transplant, and rheumatology populations, leaving dermatologists without a clear or actionable plan for their patients. This review is intended to fill that gap and serve as a quick reference tool for dermatologists navigating measles risk in the context of immunomodulatory therapy.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Dermatology, The University of Texas McGovern Medical School, Houston, Texas",
    "School of Medicine, Baylor College of Medicine, Houston, Texas",
    "Department of Dermatology, The University of Texas McGovern Medical School, Houston, Texas; Center for Clinical Studies, Webster, Texas; Correspondence to: Stephen K. Tyring, MD, PhD, MBA 6431 Fannin St, Houston, TX 77030."
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 4,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Annabel Shen, BS"
    },
    {
      "affs": [
        1
      ],
      "name": "Aileen Y. Hu, BS"
    },
    {
      "affs": [
        1
      ],
      "name": "Kevin W. Hoffman, BS"
    },
    {
      "affs": [
        2
      ],
      "name": "Stephen K. Tyring, MD, PhD, MBA"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/e0dsjehzwnsb5.bib",
  "cited_by": 0,
  "doi": "10.1016/j.jdrv.2026.09.010",
  "fulltext_url": "http://www.sciencedirect.com/science/article/pii/S2950198926001145",
  "id": "e0dsjehzwnsb5",
  "issns": [
    "2950-1989"
  ],
  "landing_url": "https://doi.org/10.1016/j.jdrv.2026.09.010",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RL1-803"
    ],
    [
      "openalex",
      "2713|Virology and Viral Diseases"
    ]
  ],
  "openalex": "W7215120129",
  "pdf_url": "https://www.jaadreviews.org/article/S2950-1989(26)00114-5/pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-30",
  "publisher": "Elsevier",
  "ris": "https://research.draconitic.com/paper/e0dsjehzwnsb5.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T13:44:35Z",
      "native_id": "b3c3bfe24575479b8f4499da73518834",
      "source": "doaj",
      "url": "https://doi.org/10.1016/j.jdrv.2026.09.010"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2713|Virology and Viral Diseases",
      "subfield": "epidemiology-public-health"
    }
  ],
  "title": "Measles risk and measles-mumps-rubella vaccination timing in dermatology patients on immunosuppressive therapy",
  "title_text": "Measles risk and measles-mumps-rubella vaccination timing in dermatology patients on immunosuppressive therapy",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T13:44:35Z",
  "url": "https://research.draconitic.com/paper/e0dsjehzwnsb5",
  "venue": "JAAD Reviews",
  "versions": []
}